-Capital Medicine 2000,7(10):36-

Clinical Observation Of The Effects of Xuezhikang On Older Hyperlipidemia Patients Associated With High Blood Viscosity Symptom

Chen Ping
(Central Hospital of Northeast China Electricity
Industry Corporation,110015 China)


INTRODUCTION

Recently, with the increasing living standard, the society is experiencing aging problem. More and more older people get high blood viscosity disorders directly leading to the increase of the occurrence of cardio-cerebrovascular diseases, which imposes great danger to the health and life quality of older people. Therefore, treating hyperlipoidemia and high blood viscosity is the key to prevent and cure cardio-cerebrovascular diseases.

From January 1997 to November of 1998, We used Xuezhikang to treat 101 older patients and observed the changes of blood viscosity and serum lipid levels during and after the trial. The following is the clinical report.

PATIENTS

101 older patients came from both outpatients and inpatients, 63 men, 38 women, aging from 60 to 79 years old with the average of 75. After disease history inquiry, physical examination and various kinds of test, patients with thyropathy, hepatic and biliary diseases or arthrolithiasis were excluded from the trial. Among these 101 patients, 41 were associated with hypertension; 35 were associated with coronary disease with stable stenocardia; 16 with obsolete myocardial infarction and 9 cases with diabetes II.


METHODS

After proper diet education, target patients ceased their administration of previous lipid-lowering medicines. Four weeks later, serum lipid and blood viscosity were re-examined and those meeting the following criteria were chosen: TC > 6.0 mmol/L, TG > 2.2 mmol/L, LDL > 3.5 mmol/L and HDL-C 1.04 mmol/L. Total blood viscosity check low cut 8.92 1.30 whereas high cut 6.29 0.61, viscosity 1.70 0.07. All the 101 patients met the above criteria. In the course of the treatment, patients took 0.6 g Xuezhikang capsule (developed by Beijing WBL Peking University Biotech Co., Ltd.), two capsules a time, twice a day, one in the morning after breakfast, the other in the evening after dinner. The treatment lasted for 4 ~ 8 weeks. Blood pressure, hepatic and renal functions, conventional blood and urine test items, blood sugar, electrocardiogram and four kinds of serum lipid concentration were examined before the treatment. Then they were re-examined once a month during the trial period. Patients could keep their life style and dietary habit in the course. However, other medicines affecting serum lipid metabolism were prohibited.

CRITERIA FOR CURATIVE EFFECTS

Curative effects were identified in the light of Guiding Standards for Clinical Study on Medicines for Cardio-cerebrovascular Diseases stipulated by the Ministry of Public Health in 1988.
Highly Effective: TC reduction > 20%; TG reduction > 40%; HDL-C increase 0.26
mmol/L.
Effective: TC reduction > 10%; TG reduction > 20%; LDL increase > 0.104 mmol/L.
Ineffective: the individual concentration did not reach the above standard.

RESULTS

The results of the study are listed in Table I, Table II and Table III.

Table I. Lipid Concentration Change before and after Xuezhikang Treatment
Index
Before treatment
4-week
after Treatment
8-week
after treatment
TC
6.71 0.49
5.18 0.76
5.24 0.64
TG
3.36 1.02
2.58 1.14
2.05 0.67
LDL-C
4.48 0.97
3.54 0.80
3.08 0.89
HDL-C
1.00 0.60
1.44 0.22
1.43 0.18
Note: P < 0.01


Table II. Curative Effect Comparison after 8 Weeks of Xuezhikang Treatment (%)
Index
Case
Highly Effective
Effective
Ineffective
Total Efficacy
n
%
n
%
n
%
n
%
TC
53
35
67.9
14
26.4
3
5.9
50
94.3
TG
43
17
39.5
18
41.9
8
18.6
35
81.4
LDL-C
22
7
25.9
13
48.2
7
25.9
15

74.0

HDL-C
17
7
41.2
8
47.1
2
11.7
15
88.3


Table III. Effects of Xuezhikang on Total Blood Viscosity after 8 Weeks Treatment
Sex
Case
Blood Low Cut Viscosity
X S
Blood High Cut Viscosity
X S
Plasma
M 63 8.92 1.30 6.29 0.68
1.70 0.07
Before Treatment
W 38 6.94 0.98 5.43 0.51
M 63 9.18 0.56 6.59 0.48
After Treatment  
          1.68 0.05
W 38 6.57 0.94 5.62 0.56  

Both Table I and Table II showed that Xuezhikang had dramatic performance in reducing the concentrations of TC, TG and LDL as well as increasing certain level of HDL. The effect became more significant after 8 weeks treatment. Xuezhikang effectively lowered TC by 94.3%; TG by 81.4%; LDL by 74.0% and HDL-C by 88.3%. Whereas Table 3 indicated that Xuezhikang could also reduce blood viscosity. In this study, with the decrease of serum lipid and blood viscosity, clinical symptoms of the 101 older hyperlipoidemia patients improved significantly with blood pressure in good control, blood sugar level going down at different extent, no occurrence of such disorders as stenocardia, chest suppression and pant. And their health status also dramatically improved. Only 2 of the 101 cases occurred with abdominal distention, 1 with headache and their symptoms lessened after the administration dosage was adjusted. Hepatic and renal functions, conventional blood and urine tests and electrocardiogram appeared normal in the examination after 4 ~ 9 weeks treatment.



DISCUSSION

At present, researchers and scholars at home and abroad have demonstrated that hyperlipoidemia and high blood viscosity are key factors directly leading to the occurrence and development of atherosclerosis and cardio-cerebrovascular diseases.

Older people have high morbidity of such disorders as hyperlipoidemia, high blood viscosity and atherosclerosis. Therefore, active treatment of hyperlipoidemia and high blood viscosity can remarkably reduce both the morbidity and mortality of cardio-cerebrovascular diseases. Now, foreign medical specialists have verified that the increase of LDL directly causes the development of coronary heart disease. And if LDL concentration goes down by 10% ~ 20%, the risk of developing coronary heart disease decrease the greatest degree. Xuezhikang capsule used in the study is developed and manufactured by Beijing WBL Peking University Biotech Co., Ltd. Remarkable curative effects have been obtained on 101 older hyperlipoidemia and high blood viscosity patients when they are treated with Xuezhikang. In particular, it has stronger performance in reducing TC than reducing TG. Meanwhile, it can significantly decrease blood viscosity and effectively prevent the development of thrombus. In addition, it facilitates patients with diabetes to decrease blood sugar. The mechanism may lie in the fact that many kinds of unsaturated fatty acids inhibit the development of TG and fatty acids, accelerate insulin secretion of pancreas islet B cell or increase the sensitivity of surrounding tissues to insulin. Therefore, after the study, it is thought that Xuezhikang is a safe and effective medicine for older patients to decrease serum lipid and blood viscosity.

REFERENCES

1.
Zhu Yan, Li Changling, Wang Yinye, Lipid Regulation Effects of Xuezhikang on Hyperlipoidemia Rabbit and Quail Models, Journal of Chinese Medicine, 1995, 30:656.
2.
Kou Zhirong, Lu Zongliang, et al, Clinical Effects of Xuezhikang on Primary Hyperlipoidemia, Chinese Journal of Internal Medicine, 1997, 36:529.
 
 
2013 Asiapharm Biotech Pte Ltd. All rights reserved.

Notices and Legal Disclaimer


Information on this web site is provided for informational purposes only and is not a substitute for professional medical advice. You should not use the information on this web site for diagnosing or treating a medical or health condition. You should carefully read all product packaging. If you have or suspect you have a medical problem, promptly contact your professional healthcare provider.

Statements and information regarding dietary supplements have not been evaluated or approved by the U.S. Food and Drug Administration. Please consult your healthcare provider before beginning any course of supplementation or treatment.